



Attorney Docket No. 270.PFUS
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Terrence C. Dahl

Serial No.: 10/540,794

Group No.: 1616

Filed: March 20, 2006

Examiner: Alton Nathaniel Pryor

For: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Commissioner for Patents
Mail Stop Amendments
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE
MAILING DATE OF EITHER A FINAL ACTION OR NOTICE
OF ALLOWANCE (37 CFR 1.97 (c))**

**TIME TRANSMITTAL OF ACCOMPANYING INFORMATION
DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,whichever occurs first.

CERTIFICATE OF MAILING


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

Date:

8/17/2007

Donna J. Macedo

(Type or print name of person mailing paper)


(Signature of person mailing paper)

CERTIFICATION OR FEE

2. Accompany this transmittal is

A. ☐ a certification as specified in 37 CFR 1.97 (e)

OR

B. ☒ the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$180.00).

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$180.00).

Fee due \$ 180.00

METHOD OF PAYMENT OF FEE

4.

☐ attached is check in the sum of \$ _____

☒ charge Account No. 07-1250 the sum of \$ 180.00

A duplicate of this request is attached.

If any additional fees are due, please charge Account No. 07-1250 .

Reg. No. 27,043

Tel. No.: (650) 522-5709



SIGNATURE OF ATTORNEY

Max Hensley

Type or print name of attorney

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404



Attorney Docket No. 270PFUS
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Terrence C. Dahl

Serial No.: 10/540,794

Group No.: 1616

Filed: March 20, 2006

Examiner: Alton Nathaniel Pryor

For: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Commissioner for Patents
Mail Stop Missing Parts
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO – 1449 – Pages
3. ☐ Identification of Prior Application in Which Listed Information Was Already Cited.

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

☒ 37 CFR 1.8 (a)
with sufficient postage as
first class mail

or

☐ 37 CFR 1.10
as "Express Mail Post
Office to Addressee" Mailing
Label
No. _____

Date: _____

8/17/07

Donna J. Macedo

(Type or print name of person mailing paper)

[Signature]
(Signature of person mailing paper)

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose. To the extent that this submission includes an International Search Report, such Report is submitted to facilitate the Examiner's analysis of the references and not out of any belief that the International Searching Authority's construction of the relevance of the references has any bearing under United States Law.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted


This application relies, under 35 U.S.C. 120, at least on the earlier filing dates of prior applications:

Serial No. _____, filed on _____

Copies of references are not supplied to the extent that they are found in the file history of the prior application(s). Copies of references that were not supplied in the prior application(s), if any, accompany this paper.

Reg. No. 27,043


Tel. No.: (650) 522-5709



SIGNATURE OF ATTORNEY
Max Hensley

Type or print name of attorney

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/P-15

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/540,794
Filing Date	March 20, 2006
First Named Inventor	Terrence C. Dahl
Art Unit	1616
Examiner Name	Alton Nathaniel Pryor
Attorney Docket Number	270.PFUS

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DE CLERQ, E. "New Developments in Anti-HIV Chemotherapy," Biochem Biophys Acta. 2002 18:1587(2-3):258-75	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.